Furthermore, in the expansion cohorts of TATTON trial, investigators evaluated the safety and efficacy of osimertinib plus savolitinib in locally advanced or metastatic, MET-amplified, EGFR mutation-positive NSCLC patients who had progressed on EGFR–TKIs [29]. The gene discussed is MET; the disease is non-small cell lung carcinoma.